DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,777,074 B2 Kramer Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,777,074 B2 Kramer Et Al US007777074 B2 (12) United States Patent (10) Patent No.: US 7,777,074 B2 Kramer et al. (45) Date of Patent: Aug. 17, 2010 (54) AMINO ACID COMPOUNDS (52) U.S. Cl. .................................... 562/512:548/335.5 (58) Field of Classification Search ................. 514/400, (75) Inventors: Ronald Kramer, Phoenix, AZ (US); 514/561, 563: 548/335.5; 562/512 hander Nikolaidis, New Kallikratia See application file for complete search history. GR (56) References Cited (73) Assignee: Estol,Inisational LLC, OTHER PUBLICATIONS Mostad et al., 1986, CAS: 104:197543.* (*) Notice: Subject to any disclaimer, the term of this Pradhan et al. publication, Journal of Chemical and Engineering patent is extended or adjusted under 35 Data, 2000, 45(1): 140-143.* U.S.C. 154(b) by 58 days. * cited by examiner (21) Appl. No.: 11/950,273 Primary Examiner Rei-tsang Shiao (22) Filed: Dec. 4, 2007 (74) Attorney, Agent, or Firm Booth Udall, PLC (65) Prior Publication Data (57) ABSTRACT US 2009/007611.0 A1 Mar. 19, 2009 An Amino Acid Compound is described. The Amino Acid Related U.S. Application Data Compound may comprise an Amino Acid and one of a Nitrate (60) Provisional application No. 60/973.229, filed on Sep. and a Nitrite. The Amino Acid may be one of Agmatine, 18, 2007 Arginine, Beta Alanine, Citrulline, Creatine, Glutamine, s L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and (51) Int. Cl. Valine. C07C 53/00 (2006.01) CO7D 233/6 (2006.01) 2 Claims, No Drawings US 7,777,074 B2 1. 2 AMINO ACID COMPOUNDS of an Amino Acid Compound comprising an Amino Acid and one of a Nitrate and a Nitrite to the human or animal. CROSS REFERENCE TO RELATED Embodiments may include the following. The Amino Acid APPLICATIONS may be Agmatine. The Amino Acid may be Beta Alanine. The Amino Acid may be Arginine. The Amino Acid may be Cit This document claims the benefit of the filing date of U.S. Provisional Patent Application 60/973,229 entitled “Amino rulline. The Amino Acid may be Creatine. The Amino Acid Acid Compounds' to Alexander Nikolaidis and Ronald may be Histidine. The Amino Acid may be Isoleucine. The Kramer which was filed on Sep. 18, 2007, the disclosure of Amino Acid may be Leucine. The Amino Acid may be Nor which is hereby incorporated entirely herein by reference. 10 valine. The Amino Acid may be Ornithine. The Amino Acid may be Valine. BACKGROUND In another aspect, the invention features a method for increasing the bioabsorption of Amino Acids. The method 1. Technical Field includes administering a pharmaceutically effective amount Aspects of this document relate generally to Amino Acid 15 of an Amino Acid Compound comprising an Amino Acid and Compounds. one of a Nitrate and a Nitrite to the human or animal. 2. Background Embodiments may include the following. The Amino Acid It is desirable to design new Amino Acid compounds that may be Agmatine. The Amino Acid may be Beta Alanine. The have properties lacking in conventional Amino Acid com Amino Acid may be Arginine. The Amino Acid may be Cit pounds, conventional Nitrate compounds, conventional rulline. The Amino Acid may be Creatine. The Amino Acid Nitrite compounds, and in single-administration Amino may be Histidine. The Amino Acid may be Isoleucine. The Acids. Amino Acid may be Leucine. The Amino Acid may be Nor SUMMARY valine. The Amino Acid may be Ornithine. The Amino Acid 25 may be Valine. In one aspect, the invention features an Amino Acid Com In another aspect, the invention features a method for pound. The Amino Acid Compound may comprise an Amino increasing the vasodilative characteristics of Amino Acids. Acid and one of a Nitrate and a Nitrite. The method includes administering a pharmaceutically effec Embodiments may comprise one or more of the following. tive amount of an Amino Acid Compound comprising an The Amino Acid may be Agmatine. The Amino Acid may be 30 Amino Acid and one of a Nitrate and a Nitrite to the human or Beta Alanine. The Amino Acid may be Arginine. The Amino animal. Acid may be Citrulline. The Amino Acid may be Creatine. Embodiments may include the following. The Amino Acid The Amino Acid may be Histidine. The Amino Acid may be may be Agmatine. The Amino Acid may be Beta Alanine. The Isoleucine. The Amino Acid may be Leucine. The Amino Amino Acid may be Arginine. The Amino Acid may be Cit Acid may be Norvaline. The Amino Acid may be Ornithine. 35 rulline. The Amino Acid may be Creatine. The Amino Acid The Amino Acid may be Valine. may be Histidine. The Amino Acid may be Isoleucine. The The Amino Acid Compound may include a pharmaceuti Amino Acid may be Leucine. The Amino Acid may be Nor cally acceptable additive. The additive may be a carrier, an excipient, a binder, a colorant, a flavoring agent, a preserva valine. The Amino Acid may be Ornithine. The Amino Acid 40 may be Valine. tive, a buffer, a dilutant, and/or combinations thereof. The Amino Acid Compound may be in the form of a cap In another aspect, the invention features a method for Sule, tablet, pill, liquid, liquid Suspension, vapor, gas, powder, increasing distribution of Amino Acids to muscles. The granulate or pulverulence. A pharmaceutically acceptable method includes administering a pharmaceutically effective additive may be used such as a carrier, excipient, binder, amount of an Amino Acid Compound comprising an Amino colorant, flavoring agent, preservative, buffer, dilutant, and 45 Acid and one of a Nitrate and a Nitrite to the human or animal. combinations thereof. Embodiments may include the following. The Amino Acid In another aspect, the invention features a process for mak may be Agmatine. The Amino Acid may be Beta Alanine. The ing an Amino Acid Compound. The method includes prepar Amino Acid may be Arginine. The Amino Acid may be Cit ing a first solution of Nitric Acid and an Amino Acid. A rulline. The Amino Acid may be Creatine. The Amino Acid mixture is then formed by adding to the first Solution a quan 50 may be Histidine. The Amino Acid may be Isoleucine. The tity of water sufficient to ionize the Nitric Acid into a Nitrate Amino Acid may be Leucine. The Amino Acid may be Nor ion. The mixture is then allowed to crystallize. valine. The Amino Acid may be Ornithine. The Amino Acid Embodiments may comprise the following. The mixture may be Valine. may be placed under vacuum prior to being allowed to crys 55 In another aspect, the invention features a method for pre tallize. venting the development of Nitrate tolerances. The method In another aspect, the invention features a process for mak includes administering a pharmaceutically effective amount ing an Amino Acid Compound. The method comprises pre of an Amino Acid Compound comprising an Amino Acid and paring a first Solution of Nitrous Acid and an Amino Acid. A one of a Nitrate and a Nitrite to the human or animal. mixture is then formed by adding to the first Solution a quan 60 Embodiments may include the following. The Amino Acid tity of water sufficient to decompose the Nitrous Acid into may be Agmatine. The Amino Acid may be Beta Alanine. The Nitric Acid. The mixture is then allowed to crystallize. Amino Acid may be Arginine. The Amino Acid may be Cit Embodiments may include the following. The mixture may rulline. The Amino Acid may be Creatine. The Amino Acid be placed under vacuum prior to being allowed to crystallize. may be Histidine. The Amino Acid may be Isoleucine. The In another aspect, the invention features a method for 65 Amino Acid may be Leucine. The Amino Acid may be Nor increasing the water solubility of Amino Acids. The method valine. The Amino Acid may be Ornithine. The Amino Acid includes administering a pharmaceutically effective amount may be Valine. US 7,777,074 B2 3 4 DESCRIPTION The R group for the Amino Acid Creatine is: Overview HN H A Compounds containing both a carboxyl group and an 5 N amino group are typically known as Amino Acids. Amino Acids typically have the basic formula X-R, wherein X is: -N CH-COOH 10 Creatine is a nonessential Amino Acid and is also a nitrog enous organic acid. Creatine is independently manufactured by the human body, and does not need to be obtained directly Amino Acids typically differ from one another with respect through dietary intake. Creatine plays a significant role in to the structure of the R group. It is the structure of the R group 15 providing muscles with energy. Creatine is presently used in that typically determines the individuality and character of the dietary Supplement industry to Supplement Creatine pro each Amino Acid. duction in the body. Creatine is also presently used in the For example, the R group for the Amino Acid Arginine is: dietary Supplement industry to increase muscle-mass gains, improve athletic performance and strength. Creatine, by 2O itself, has no vasodilating properties. Citrulline is also water insoluble, which reduces its bioavailability and limits the in-chi-ch-ch, forms in which Citrulline may be effectively used. = NH The R group for the Amino Acid Glutamine is: NH2 25 HN-C-CH-CH Arginine is characterized as a nonessential Amino Acid. Spe O cifically, Arginine can be independently manufactured by the human body, and does not need to be obtained directly 30 through dietary intake. Arginine plays a significant role in Glutamine is a nonessential Amino Acid. Glutamine is the healing, cell division, immune function, the elimination of most abundant naturally occurring, non-essential amino acid ammonia from the body and the release of hormones.
Load more

Recommended publications
  • Insights Into the Molecular Basis for Substrate Binding and Specificity of the Wild-Type L-Arginine/Agmatine Antiporter Adic
    Insights into the molecular basis for substrate binding and specificity of the wild-type L-arginine/agmatine antiporter AdiC Hüseyin Ilgüa,b,1, Jean-Marc Jeckelmanna,b,1, Vytautas Gapsysc, Zöhre Ucuruma,b, Bert L. de Grootc, and Dimitrios Fotiadisa,b,2 aInstitute of Biochemistry and Molecular Medicine, University of Bern, CH-3012 Bern, Switzerland; bSwiss National Centre of Competence in Research TransCure, University of Bern, CH-3012 Bern, Switzerland; and cComputational Biomolecular Dynamics Group, Max-Planck-Institute for Biophysical Chemistry, D-37077 Goettingen, Germany Edited by Christopher Miller, Howard Hughes Medical Institute, Brandeis University, Waltham, MA, and approved July 26, 2016 (received for review April 4, 2016) Pathogenic enterobacteria need to survive the extreme acidity of Arg-bound states (10). The two outward-open, substrate-free the stomach to successfully colonize the human gut. Enteric bacteria structures are at the reasonable and moderate resolutions of 3.2 Å circumvent the gastric acid barrier by activating extreme acid- (8) and 3.6 Å (9), respectively, and the only ones available of wild- resistance responses, such as the arginine-dependent acid resistance type AdiC (AdiC-wt). The two other structures are with bound system. In this response, L-arginine is decarboxylated to agmatine, Arg and at 3-Å resolution, and could only be obtained as a result thereby consuming one proton from the cytoplasm. In Escherichia of the introduction of specific point mutations: AdiC-N22A (10) coli,theL-arginine/agmatine antiporter AdiC facilitates the export and AdiC-N101A (11). The N101A mutation results in a defective of agmatine in exchange of L-arginine, thus providing substrates for AdiC protein unable to bind Arg and with a dramatically de- further removal of protons from the cytoplasm and balancing the creased turnover rate compared with wild-type (11).
    [Show full text]
  • Separation of Isomers <Emphasis Type="Italic">L </Emphasis>-Alanine and Sarcosine in Urine by Electrospra
    SHORT COMMUNICATION Separation of Isomers L-Alanine and Sarcosine in Urine by Electrospray Ionization and Tandem Differential Mobility Analysis-Mass Spectrometry Pablo Martínez-Lozanoa and Juan Rusb a Institute for Biomedical Technologies-National Research Council, Milan, Italy b SEADM, Valladolid, Spain Sarcosine, an isomer of L-alanine, has been proposed as a prostate cancer progression biomarker [1]. Both compounds are detected in urine, where the measured sarcosine/alanine ratio has been found to be higher in prostate biopsy-positive group versus controls. We present here preliminary evidence showing that urine samples spiked with sarcosine/alanine can be partially resolved in 3 min via tandem differential mobility analysis-mass spectrometry (DMA-MS). Based on the calibration curves obtained for two mobility peaks, we finally estimate their concentration ratio in urine. (J Am Soc Mass Spectrom 2010, 21, 1129–1132) © 2010 American Society for Mass Spectrometry rostate cancer is a leading cause of death among the tive-ion mode at the DMA entrance slit. Our nanospray male population. Sarcosine, an isomer of alanine, parameters were: capillary 360 ␮m o.d., 50 ␮m i.d., length Pwas recently proposed as a prostate cancer progres- 22 cm, driving pressure 75 mbar, and 3.8 kV. The ions sion biomarker [1]. In particular, the sarcosine/alanine entered the separation region propelled by an electric field ratio was found to be significantly higher in urine derived and against a counterflow gas (0.2 L/min). Sheath gas from biopsy-positive prostate cancer patients compared flow was kept constant, and the classification voltage was with biopsy-negative controls.
    [Show full text]
  • Beta Alanine
    PERFORMANCE ENHANCERS FACTS AND BOTTOM LINE BETA ALANINE What is it? B-alanine is a naturally occurring amino acid (a non-essential amino acid) not used by the body to make muscle tissue. Rather, research has shown that B-alanine works by increasing the muscle content of an important compound – carnosine. In fact, the production of carnosine is limited by the availability of B-alanine. Carnosine is highly concentrated in muscle tissue where its role is primarily to soak up hydrogen ions. Does it work? B-alanine is one of the few dietary supplements that actually have good scientific evidence that it can possibly enhance performance. How does it work? When you exercise intensely the body produces hydrogen ions. The longer you exercise the more hydrogen ions you produce and this reduces the pH level in your muscles. Muscles work best in a very specific pH range and when the pH drops below that level then muscular performance also starts to decrease. Anything that helps to prevent or delay that drop in pH will help delay muscle fatigue. This is where B-alanine has proven to be very helpful. Beta-alanine increases the levels of carnosine in your slow and fast twitch muscle fibers and carnosine is a buffer that basically soaks up hydrogen ions and so reduces the drop in pH. By keeping your hydrogen ion levels lower, B-alanine allows you to train harder and longer. The bottom line is that B-alanine works by increasing the hydrogen ion buffering abilities of your muscles. What benefits does it offer? B-alanine has been shown to increase muscle strength, increase muscle mass, increase anaerobic endurance, increase aerobic endurance and increase exercise capacity.
    [Show full text]
  • Poly(L-Alanine) As a Universal Reference Material for Understanding Protein Energies and Structures TERESA HEAD-GORDON, FRANK H
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 11513-11517, December 1992 Biophysics Poly(L-alanine) as a universal reference material for understanding protein energies and structures TERESA HEAD-GORDON, FRANK H. STILLINGER, MARGARET H. WRIGHT, AND DAVID M. GAY AT&T Bell Laboratories, Murray Hill, NJ 07974 Contributed by Frank H. Stillinger, June 17, 1992 ABSTRACT We present a proposition, the "poly(L- alanine) hypothesis," which asserts that the native backbone geometry for any polypeptide or protein of M residues has a closely mimicking, mechanically stable, image in poly(L- POLY-L-ALANINE alanine) of the same number of residues. Using a molecular co mechanics force field to represent the relevant potential energy a: hypersurfaces, we have carried out calculations over a wide z range of M values to show that poly(L-alanine) possesses the w structural versatility necessary to satisfy the proposition. These w include poly(L-alanine) representatives of minima correspond- U- ing to secondary and supersecondary structures, as well as PROTEIN poly(L-alanine) images for tertiary structures of the naturally occurring proteins bovine pancreatic trypsin inhibitor, crambin, ribonuclease A, and superoxide dismutase. The suc- cessful validation of the hypothesis presented in this paper BACKBONE COORDINATES indicates that poly(L-alanine) will serve as a good reference FIG. 1. Topographic basis ofthe poly(L-alanine) hypothesis. Free material in thermodynamic perturbation theory and calcula- energy hypersurfaces are compared for a given protein and for tions aimed at evaluating relative free energies for competing poly(L-alanine) with the same number of residues. candidate tertiary structures in real polypeptides and proteins.
    [Show full text]
  • Alcohol Use Disorder
    Section: A B C D E Resources References Alcohol Use Disorder (AUD) Tool This tool is designed to support primary care providers (family physicians and primary care nurse practitioners) in screening, diagnosing and implementing pharmacotherapy treatments for adult patients (>18 years) with Alcohol Use Disorder (AUD). Primary care providers should routinely offer medication for moderate and severe AUD. Pharmacotherapy alone to treat AUD is better than no therapy at all.1 Pharmacotherapy is most effective when combined with non-pharmacotherapy, including behavioural therapy, community reinforcement, motivational enhancement, counselling and/or support groups. 2,3 TABLE OF CONTENTS pg. 1 Section A: Screening for AUD pg. 7 Section D: Non-Pharmacotherapy Options pg. 4 Section B: Diagnosing AUD pg. 8 Section E: Alcohol Withdrawal pg. 5 Section C: Pharmacotherapy Options pg. 9 Resources SECTION A: Screening for AUD All patients should be screened routinely (e.g. annually or when indicators are observed) with a recommended tool like the AUDIT. 2,3 It is important to screen all patients and not just patients eliciting an index of suspicion for AUD, since most persons with AUD are not recognized. 4 Consider screening for AUD when any of the following indicators are observed: • After a recent motor vehicle accident • High blood pressure • Liver disease • Frequent work avoidance (off work slips) • Cardiac arrhythmia • Chronic pain • Rosacea • Insomnia • Social problems • Rhinophyma • Exacerbation of sleep apnea • Legal problems Special Patient Populations A few studies have reviewed AUD in specific patient populations, including youth, older adults and pregnant or breastfeeding patients. The AUDIT screening tool considered these populations in determining the sensitivity of the tool.
    [Show full text]
  • Amino Acid Chemistry
    Handout 4 Amino Acid and Protein Chemistry ANSC 619 PHYSIOLOGICAL CHEMISTRY OF LIVESTOCK SPECIES Amino Acid Chemistry I. Chemistry of amino acids A. General amino acid structure + HN3- 1. All amino acids are carboxylic acids, i.e., they have a –COOH group at the #1 carbon. 2. All amino acids contain an amino group at the #2 carbon (may amino acids have a second amino group). 3. All amino acids are zwitterions – they contain both positive and negative charges at physiological pH. II. Essential and nonessential amino acids A. Nonessential amino acids: can make the carbon skeleton 1. From glycolysis. 2. From the TCA cycle. B. Nonessential if it can be made from an essential amino acid. 1. Amino acid "sparing". 2. May still be essential under some conditions. C. Essential amino acids 1. Branched chain amino acids (isoleucine, leucine and valine) 2. Lysine 3. Methionine 4. Phenyalanine 5. Threonine 6. Tryptophan 1 Handout 4 Amino Acid and Protein Chemistry D. Essential during rapid growth or for optimal health 1. Arginine 2. Histidine E. Nonessential amino acids 1. Alanine (from pyruvate) 2. Aspartate, asparagine (from oxaloacetate) 3. Cysteine (from serine and methionine) 4. Glutamate, glutamine (from α-ketoglutarate) 5. Glycine (from serine) 6. Proline (from glutamate) 7. Serine (from 3-phosphoglycerate) 8. Tyrosine (from phenylalanine) E. Nonessential and not required for protein synthesis 1. Hydroxyproline (made postranslationally from proline) 2. Hydroxylysine (made postranslationally from lysine) III. Acidic, basic, polar, and hydrophobic amino acids A. Acidic amino acids: amino acids that can donate a hydrogen ion (proton) and thereby decrease pH in an aqueous solution 1.
    [Show full text]
  • Proline- and Alanine-Rich N-Terminal Extension of the Basic Bovine P-Crystallin B1 Chains
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Volume 161, number 2 FEBS 0790 September 1983 Proline- and alanine-rich N-terminal extension of the basic bovine P-crystallin B1 chains G.A.M. Berbers, W.A. Hoekman, H. Bloemendal, W.W. de Jong, T. Kleinschmidt* and G. Braunitzer* Laboratorium voor Biochemie, Universiteit van Nijmegen, Geert Grooteplein Noord 21, 6525 EZ Nijmegen, The Netherlands and *Max-Planck-Institut ft’ir Biochemie, Abteilung Proteinchemie, D-8033 Martinsried bei Miinchen, FRG Received 22 June 1983 The amino acid sequence of the N-terminal region of the two basic bovine &crystallin B1 chains has been analyzed. The results reveal that @Bibis derived in vivo from the primary gene product @la by removal of a short N-terminal sequence. It appears that them1 chains have the same domain structure as observed in other /3- and y-crystallin chains. They have, however, a very long N-terminal extension in comparison with other &chains. This extension is mainly composed of a remarkable Pro- and Ala-rich sequence, which suggests an interaction of these structural proteins with the cytoskeleton and/or the plasma membranes of the lens cells. Protein sequence Bovine &crystallin N-terminal extension Proline- and aianine-rich Domain structure 1. INTRODUCTION 33 000 and 31000, respectively, are characteristic for fltikt, [ 111. ,8Fha is a primary gene product, from The crystallins are evolutionary highly conserv- which ,8&b arises by post-translational modifica- ed structural eye lens proteins, which can be divid; tion [lo-121, most probably a proteolytic step ed into 4 classes: (Y-,,&, y- and t-crystallin [ 11.
    [Show full text]
  • The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats
    W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 4-2017 The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats Justin P. Canakis College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Animal Sciences Commons, Exercise Science Commons, Laboratory and Basic Science Research Commons, and the Other Nutrition Commons Recommended Citation Canakis, Justin P., "The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats" (2017). Undergraduate Honors Theses. Paper 1128. https://scholarworks.wm.edu/honorstheses/1128 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. 1 2 Title Page……………………………………………………………………………………...…..1 Abstract…………………………………………………………………………………………....5 Acknowledgement……………………………………………………………………….………..6 Background.………………………………………………………………………..……………...7 DSEHA and its Effect on the VMS Industry………………...……………………………7 History of Adverse Side Effects from Pre-Workout Supplements ………….……………8 Ingredient Analysis ………………………………………..……………….……………..……....9 2.5g Beta-Alanine…………………………..……………………………………………..9 1g Creatine Nitrate……………………………...……………………………………..…12 500mg L-Leucine……………………………………………………………………...…16 500mg Agmatine Sulfate……………………….………………………………..………18
    [Show full text]
  • The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by College of William & Mary: W&M Publish W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 4-2017 The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats Justin P. Canakis College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Animal Sciences Commons, Exercise Science Commons, Laboratory and Basic Science Research Commons, and the Other Nutrition Commons Recommended Citation Canakis, Justin P., "The Efficacy and Safety of Six-Weeks of Pre-Workout Supplementation in Resistance Trained Rats" (2017). Undergraduate Honors Theses. Paper 1128. https://scholarworks.wm.edu/honorstheses/1128 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. 1 2 Title Page……………………………………………………………………………………...…..1 Abstract…………………………………………………………………………………………....5 Acknowledgement……………………………………………………………………….………..6 Background.………………………………………………………………………..……………...7 DSEHA and its Effect on the VMS Industry………………...……………………………7 History of Adverse Side Effects from Pre-Workout Supplements ………….……………8 Ingredient Analysis ………………………………………..……………….……………..……....9 2.5g Beta-Alanine…………………………..……………………………………………..9
    [Show full text]
  • Detection of Cyanotoxins, Β-N-Methylamino-L-Alanine and Microcystins, from a Lake Surrounded by Cases of Amyotrophic Lateral Sclerosis
    Toxins 2015, 7, 322-336; doi:10.3390/toxins7020322 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Article Detection of Cyanotoxins, β-N-methylamino-L-alanine and Microcystins, from a Lake Surrounded by Cases of Amyotrophic Lateral Sclerosis Sandra Anne Banack 1, Tracie Caller 2,†, Patricia Henegan 3,†, James Haney 4,†, Amanda Murby 4, James S. Metcalf 1, James Powell 1, Paul Alan Cox 1 and Elijah Stommel 3,* 1 Institute for Ethnomedicine, PO Box 3464, Jackson, WY 83001, USA; E-Mails: [email protected] (S.A.B.); [email protected] (J.S.M.); [email protected] (J.P.); [email protected] (P.A.C.) 2 Cheyenne Regional Medical Group, Cheyenne, WY 82001, USA; E-Mail: [email protected] 3 Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA; E-Mail: [email protected] 4 Department of Biological Sciences, University of New Hampshire, Durham, NH 03824, USA; E-Mails: [email protected] (J.H.); [email protected] (A.M.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-603-650-8615; Fax: +1-603-650-6233. Academic Editor: Luis M. Botana Received: 19 November 2014 / Accepted: 21 January 2015 / Published: 29 January 2015 Abstract: A cluster of amyotrophic lateral sclerosis (ALS) has been previously described to border Lake Mascoma in Enfield, NH, with an incidence of ALS approximating 25 times expected. We hypothesize a possible association with cyanobacterial blooms that can produce β-N-methylamino-L-alanine (BMAA), a neurotoxic amino acid implicated as a possible cause of ALS/PDC in Guam.
    [Show full text]
  • Monopeptide Versus Monopeptoid: Insights on Structure and Hydration of Aqueous Alanine and Sarcosine Via X-Ray Absorption Spectroscopy
    4702 J. Phys. Chem. B 2010, 114, 4702–4709 Monopeptide versus Monopeptoid: Insights on Structure and Hydration of Aqueous Alanine and Sarcosine via X-ray Absorption Spectroscopy Janel S. Uejio,†,‡ Craig P. Schwartz,†,‡ Andrew M. Duffin,†,‡ Alice England,†,‡ David Prendergast,§ and Richard J. Saykally*,†,‡ Department of Chemistry, UniVersity of California, Berkeley, California 94720-1460 and Chemical Sciences DiVision, Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720 ReceiVed: NoVember 19, 2009; ReVised Manuscript ReceiVed: March 3, 2010 Despite the obvious significance, the aqueous interactions of peptides remain incompletely understood. Their synthetic analogues called peptoids (poly-N-substituted glycines) have recently emerged as a promising biomimetic material, particularly due to their robust secondary structure and resistance to denaturation. We describe comparative near-edge X-ray absorption fine structure spectroscopy studies of aqueous sarcosine, the simplest peptoid, and alanine, its peptide isomer, interpreted by density functional theory calculations. The sarcosine nitrogen K-edge spectrum is blue shifted with respect to that of alanine, in agreement with our calculations; we conclude that this shift results primarily from the methyl group substitution on the nitrogen of sarcosine. Our calculations indicate that the nitrogen K-edge spectrum of alanine differs significantly between dehydrated and hydrated scenarios, while that of the sarcosine zwitterion is less affected by hydration. In contrast, the computed sarcosine spectrum is greatly impacted by conformational variations, while the alanine spectrum is not. This relates to a predicted solvent dependence for alanine, as compared to sarcosine. Additionally, we show the theoretical nitrogen K-edge spectra to be sensitive to the degree of hydration, indicating that experimental X-ray spectroscopy may be able to distinguish between bulk and partial hydration, such as found in confined environments near proteins and in reverse micelles.
    [Show full text]
  • Alcoholic Liver Disease Your Role Is Essential in Preventing, Detecting, and Co-Managing Alcoholic Liver Disease in Inpatient and Ambulatory Settings
    Preventing drinking relapse in patients with alcoholic liver disease Your role is essential in preventing, detecting, and co-managing alcoholic liver disease in inpatient and ambulatory settings Gerald Scott Winder, MD lcohol use disorder (AUD) is a mosaic of psychiatric and Assistant Professor medical symptoms. Alcoholic liver disease (ALD) in its acute Department of Psychiatry University of Michigan Health System and chronic forms is a common clinical consequence of long- Ann Arbor, Michigan A standing AUD. Patients with ALD require specialized care from pro- Jessica Mellinger, MD, MSc fessionals in addiction, gastroenterology, and psychiatry. However, Clinical Lecturer medical specialists treating ALD might not regularly consider medi- Department of Internal Medicine University of Michigan Health System cations to treat AUD because of their limited experience with the Ann Arbor, Michigan drugs or the lack of studies in patients with significant liver disease.1 Robert J. Fontana, MD Similarly, psychiatrists might be reticent to prescribe medications for Professor of Medicine AUD, fearing that liver disease will be made worse or that they will Division of Gastroenterology cause other medical complications. As a result, patients with ALD Department of Internal Medicine University of Michigan Health System might not receive care that could help treat their AUD (Box, page 24). Ann Arbor, Michigan Given the high worldwide prevalence and morbidity of ALD,2 gen- Disclosures eral and subspecialized psychiatrists routinely evaluate patients with Dr. Winder and Dr. Mellinger report no financial AUD in and out of the hospital. This article aims to equip a psychia- relationships with any company whose products are mentioned in this article or with manufacturers of trist with: competing products.
    [Show full text]